Adlai Nortye signs clinical collaborations for AN4035
- Adlai Nortye signed clinical collaboration and supply agreements with Lilly and Merck KGaA for its AN4035 Phase I trial.
- The partnerships secure free cetuximab to lower operational costs, with the stock trading down at $12.22.
- The company plans to evaluate the antibody-drug conjugate both alone and in combination to target specific solid tumors.
Adlai Nortye (NASDAQ:ANL) signed two supply agreements with Lilly and Merck KGaA to evaluate AN4035 alongside cetuximab.
The partnerships support an ongoing Phase I trial targeting patients with CEACAM5-enriched, RAS-addicted solid tumors.
AN4035 is an investigational antibody-drug conjugate designed to deliver an inhibitor payload directly into specific tumor cells.
Adlai Nortye stated that Lilly will supply cetuximab at no cost to participating United States testing sites.
The company expects these collaborations to advance its clinical pipeline.
Merck KGaA will simultaneously supply the complementary drug at no cost for trial locations across Australia and China.
The clinical evaluation of safety, tolerability, and preliminary efficacy will proceed across treatment arms on a staggered schedule.
